Renal Denervation in Patients With Refractory Hypertension

Medtronic Vascular3 sites in 1 country35 target enrollmentSeptember 2008

ConditionsHypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hypertension
Sponsor: Medtronic Vascular
Enrollment: 35
Locations: 3
Primary Endpoint: Safety - complications associated with delivery and/or use of the Ardian Catheter, adverse renal events, electrolyte disturbances, hemodynamic events.
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of refractory hypertension.

Registry

clinicaltrials.gov

Start Date

September 2008

End Date

May 2013

Last Updated

11 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Medtronic Vascular

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Systolic blood pressure of 160 mmHg or greater
•On 3 or more antihypertensive medications
•eGFR \>= 45 mL/min

Exclusion Criteria

•Renal artery abnormalities
•Known secondary hypertension attributable to a cause other than sleep apnea
•MI, angina, CVA within 6 months
•Type 1 diabetes

Outcomes

Primary Outcomes

Safety - complications associated with delivery and/or use of the Ardian Catheter, adverse renal events, electrolyte disturbances, hemodynamic events.

Time Frame: Through 3 years